Sangamo Therapeutics (SGMOQ) Net Equity Issued and Repurchased (2010 - 2025)

Sangamo Therapeutics' Net Equity Issued and Repurchased history runs 16 years deep, the most recent figure standing at -$106000.0 for Q3 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$106000.0 in Q3 2025; TTM through Dec 2025 was $21.5 million, a 1.72% decrease from a year earlier, with the FY2025 full-year figure at $21.5 million, down 1.72% from the prior year.
• Net Equity Issued and Repurchased eased to -$106000.0 in Q3 2025 per SGMOQ's latest filing, from $11.2 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $64.7 million in Q3 2022 and bottomed at -$13.6 million in Q2 2021.
• The 5-year median for Net Equity Issued and Repurchased is $11.2 million (2025), against an average of $13.1 million.
• Across the five-year window, Net Equity Issued and Repurchased slumped 1245.49% in 2021 and surged 1254.71% in 2023, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $25.0 million in 2021, then slipped by 24.05% to $19.0 million in 2022, then tumbled by 99.99% to $1000.0 in 2023, then plunged by 6600.0% to -$65000.0 in 2024, then sank by 63.08% to -$106000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Net Equity Issued and Repurchased figures stand at -$106000.0 (Q3 2025), $11.2 million (Q2 2025), and $10.4 million (Q1 2025).